Outpatient Surgery Magazine

Special Outpatient Surgery Edition - Gastroenterology - January 2019

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/1070678

Contents of this Issue

Navigation

Page 16 of 58

the average after surgery is about 3. Seeing those dramatic improve- ments is very rewarding, and our patients are very satisfied. We've been doing TIFs for a rel- atively short time period, so it will be interesting to see what kind of long-term results we achieve. But the available data from our first cases are encouraging, and the patients we had in 2016 are still doing wonderfully. I recently talked to one woman who'd previ- ously had to sleep upright for years. She's thrilled. Instead of sleeping in a recliner, she can sleep lying down, with her hus- band, in a normal bed. We've had a small number of recurrences, but they've been pri- marily compliance-related. We explain to patients what they can do and what they can eat in Week 1 after the procedure, in Week 2, in Week 3 and so on. We also tell them to keep taking their medica- tions for the duration of their recovery, and we taper them off slowly. Most are weaned off com- pletely by 3 months and can start Janice TIF 2.0 Procedure A Safe, Durable Clinical Solution to Manage Troublesome GERD SymptomT With a strong record of clinical success, proven in multiple randomized clinical trials, you can be certain the TIF® procedure will help your patients get back to living. 81% of TIF patients no longer use PPIs daily 1 84% Esophagitis healed or improved one grade 2 81% Significantly improved quality of life scores 3 www.EndoGastricSolutions.com 1 Across 11 studies in 568 patients reporting >6 months PPI use. Across 3 studies in 120 patients at >5 years 78% report no daily PPI use. 2 Across 2 studies in 56 patients reporting >36 months on follow-up endoscopy 3 Across 10 studies in 545 patients reporting >6 months follow-up on GERD-HRQL (p<0.001) The TIF® procedure is designed to treat GERD symptoms with the EsophyX® technology – a cleared device. Results may vary; visit GERDHelp.com for clinical data. EndoGastric Solutions, Inc. is the manufacturer and owner of these trademarks: TIF, EsophyX and SerosaFuse. ©2018 All rights reserved. NP02456-01G GERD has taken a lot from your patients. Help Janice re-claim herself.

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Special Outpatient Surgery Edition - Gastroenterology - January 2019